Efficacy and safety of co-administration of resveratrol with meloxicam in patients with knee osteoarthritis: a pilot interventional study

Saad Abdulrahman Hussain,1 Bushra Hassan Marouf,2 Ziyad Serdar Ali,3 Runj Simko Ahmmad1 1Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Rafidain University College, Al-Rafidain, Baghdad, Iraq; 2Department of Pharmacology and Toxicology, College of Pharmacy, University of Sulaima...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hussain SA, Marouf BH, Ali ZS, Ahmmad RS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Resveratrol meloxicam knee OA WOMAC pain severity safety Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/eefa228ff4c745dab72a6777022d77c8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:eefa228ff4c745dab72a6777022d77c8
record_format	dspace
spelling	oai:doaj.org-article:eefa228ff4c745dab72a6777022d77c82021-12-02T04:47:00ZEfficacy and safety of co-administration of resveratrol with meloxicam in patients with knee osteoarthritis: a pilot interventional study1178-1998https://doaj.org/article/eefa228ff4c745dab72a6777022d77c82018-09-01T00:00:00Zhttps://www.dovepress.com/efficacy-and-safety-of-co-administration-of-resveratrol-with-meloxicam-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Saad Abdulrahman Hussain,1 Bushra Hassan Marouf,2 Ziyad Serdar Ali,3 Runj Simko Ahmmad1 1Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Rafidain University College, Al-Rafidain, Baghdad, Iraq; 2Department of Pharmacology and Toxicology, College of Pharmacy, University of Sulaimani, Sulaimani, Kurdistan, Iraq; 3Department of Rheumatology and Orthopedics, Shar Teaching Hospital, Sulaimani, Kurdistan, Iraq Background and aim: Resveratrol shows remarkable anti-inflammatory activities in experimental models. This study aims to evaluate the effect of resveratrol, as an adjuvant with meloxicam (Mlx), on the pain and functional activity during a 90-day period and monitor the adverse effects on kidney and liver functions, lipid profile, and hematological markers.Patients and methods: This study was a double-blind, placebo-controlled, randomized multi-center study that involved 110 patients with knee osteoarthritis (OA) and was performed at Sulaimani City, Iraq, from December 2016 to September 2017. To assess the effects of Mlx with or without resveratrol, pain severity and functional disability were evaluated at baseline and after 90 days using the Western Ontario and McMaster Universities Osteoarthritis Index. Fasting blood was collected to evaluate the lipid profile markers, hematological picture, and liver and kidney functions, in addition to vitamin D level.Results: Resveratrol significantly improves pain, functions, and associated symptoms compared with placebo. The clinical and biochemical markers indicated that 500 mg/day of resveratrol, as an adjuvant with Mlx, is safe and well tolerated by the knee OA patients.Conclusion: Resveratrol, as an “add-on” medication with Mlx, was superior in terms of safety and efficacy to Mlx alone for the treatment of pain and improvement of physical function in patients with knee OA. Keywords: resveratrol, meloxicam, knee OA, WOMAC, alternative medicine, OA painHussain SAMarouf BHAli ZSAhmmad RSDove Medical PressarticleResveratrolmeloxicamknee OAWOMACpain severitysafetyGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 13, Pp 1621-1630 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Resveratrol meloxicam knee OA WOMAC pain severity safety Geriatrics RC952-954.6
spellingShingle	Resveratrol meloxicam knee OA WOMAC pain severity safety Geriatrics RC952-954.6 Hussain SA Marouf BH Ali ZS Ahmmad RS Efficacy and safety of co-administration of resveratrol with meloxicam in patients with knee osteoarthritis: a pilot interventional study
description	Saad Abdulrahman Hussain,1 Bushra Hassan Marouf,2 Ziyad Serdar Ali,3 Runj Simko Ahmmad1 1Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Rafidain University College, Al-Rafidain, Baghdad, Iraq; 2Department of Pharmacology and Toxicology, College of Pharmacy, University of Sulaimani, Sulaimani, Kurdistan, Iraq; 3Department of Rheumatology and Orthopedics, Shar Teaching Hospital, Sulaimani, Kurdistan, Iraq Background and aim: Resveratrol shows remarkable anti-inflammatory activities in experimental models. This study aims to evaluate the effect of resveratrol, as an adjuvant with meloxicam (Mlx), on the pain and functional activity during a 90-day period and monitor the adverse effects on kidney and liver functions, lipid profile, and hematological markers.Patients and methods: This study was a double-blind, placebo-controlled, randomized multi-center study that involved 110 patients with knee osteoarthritis (OA) and was performed at Sulaimani City, Iraq, from December 2016 to September 2017. To assess the effects of Mlx with or without resveratrol, pain severity and functional disability were evaluated at baseline and after 90 days using the Western Ontario and McMaster Universities Osteoarthritis Index. Fasting blood was collected to evaluate the lipid profile markers, hematological picture, and liver and kidney functions, in addition to vitamin D level.Results: Resveratrol significantly improves pain, functions, and associated symptoms compared with placebo. The clinical and biochemical markers indicated that 500 mg/day of resveratrol, as an adjuvant with Mlx, is safe and well tolerated by the knee OA patients.Conclusion: Resveratrol, as an “add-on” medication with Mlx, was superior in terms of safety and efficacy to Mlx alone for the treatment of pain and improvement of physical function in patients with knee OA. Keywords: resveratrol, meloxicam, knee OA, WOMAC, alternative medicine, OA pain
format	article
author	Hussain SA Marouf BH Ali ZS Ahmmad RS
author_facet	Hussain SA Marouf BH Ali ZS Ahmmad RS
author_sort	Hussain SA
title	Efficacy and safety of co-administration of resveratrol with meloxicam in patients with knee osteoarthritis: a pilot interventional study
title_short	Efficacy and safety of co-administration of resveratrol with meloxicam in patients with knee osteoarthritis: a pilot interventional study
title_full	Efficacy and safety of co-administration of resveratrol with meloxicam in patients with knee osteoarthritis: a pilot interventional study
title_fullStr	Efficacy and safety of co-administration of resveratrol with meloxicam in patients with knee osteoarthritis: a pilot interventional study
title_full_unstemmed	Efficacy and safety of co-administration of resveratrol with meloxicam in patients with knee osteoarthritis: a pilot interventional study
title_sort	efficacy and safety of co-administration of resveratrol with meloxicam in patients with knee osteoarthritis: a pilot interventional study
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/eefa228ff4c745dab72a6777022d77c8
work_keys_str_mv	AT hussainsa efficacyandsafetyofcoadministrationofresveratrolwithmeloxicaminpatientswithkneeosteoarthritisapilotinterventionalstudy AT maroufbh efficacyandsafetyofcoadministrationofresveratrolwithmeloxicaminpatientswithkneeosteoarthritisapilotinterventionalstudy AT alizs efficacyandsafetyofcoadministrationofresveratrolwithmeloxicaminpatientswithkneeosteoarthritisapilotinterventionalstudy AT ahmmadrs efficacyandsafetyofcoadministrationofresveratrolwithmeloxicaminpatientswithkneeosteoarthritisapilotinterventionalstudy
_version_	1718401044186136576

Efficacy and safety of co-administration of resveratrol with meloxicam in patients with knee osteoarthritis: a pilot interventional study

Ejemplares similares